New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Increasing the number of steps you take every day may slow cognitive decline in older adults who already have biological signs of early Alzheimer’s disease, according to a new observational study. The ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. New research bolsters evidence that people with early signs of Alzheimer’s can take ...

Few diagnoses carry the devastating weight of dementia, which heralds loss, decline and inevitable death. The condition is the biggest killer in the UK, and cases are set to soar. “One in three people ...

UCLA scientists mined millions of electronic health records and uncovered four distinct “roadways” that funnel people toward Alzheimer’s—ranging from mental-health struggles to vascular troubles.

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression Endocrinologist Daniel ...